Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2007, p. 3175-3183, Vol. 45, No. 10
0095-1137/07/$08.00+0 doi:10.1128/JCM.00702-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Bactériologie,1 Pneumologie Pédiatrie, Hôpital Armand Trousseau, Assistance Publique-Hôpitaux de Paris (APHP), INSERM UMR S-719, 75012 Paris, France,3 Univ Paris-Sud, Institut de Génétique et Microbiologie, Orsay F-91405, France, and CNRS, Orsay F-91405, France,2 Division de Microbiologie Analytique, Centre d'Etudes du Bouchet, Vert le Petit, France4
Received 30 March 2007/ Returned for modification 1 June 2007/ Accepted 21 July 2007
|
|
|---|
|
|
|---|
P. aeruginosa is widely distributed in the environment, and it is not clear how the patients become infected. Although cross-infection between unrelated CF patients attending the same health center is believed to be uncommon, several studies have shown that some clones may be responsible for the infection of multiple patients (1, 5, 26, 37). However, it is not known whether these clones are more pathogenic than those isolated sporadically (34). Although most patients harbor a single genotype, some patients are colonized with multiple genotypes (41). A study by Munck et al. has shown that efficient and early antibiotic therapy allowed the elimination of the organisms responsible for primary colonization and that chronic infection was caused by another strain (25).
In order to determine the origin of primary colonization and to detect infections in several patients with the same strain, it is necessary to genotype isolates sequentially. Ideally, all the isolates recovered from CF patients should be genotyped to allow epidemiological surveillance of this infection. The availability of molecular methods for genotyping with a high degree of discriminatory power has opened the way to epidemiological studies. The most frequently used techniques are pulsed-field gel electrophoresis (PFGE) and ribotyping, which remain relatively expensive and time-consuming (3, 12, 39). Despite improvements in the protocol, in many laboratories PFGE is not being used on a routine basis for the genotyping of P. aeruginosa (10).
Other techniques use repetitive-element-based PCR and are simple and fast, but they lack interlaboratory reproducibility (37). The use of these techniques has made it possible to investigate local P. aeruginosa isolates within a center, but intercenter comparisons are almost impossible. A multilocus sequence typing scheme which could be a portable technique was developed, but its cost makes it impossible for use in small laboratories on a routine basis (7).
There is thus a need for a highly informative genotyping method which could be applied to a large number of samples at a low cost and which would allow interlaboratory comparisons. Multiple-locus variable-number tandem-repeat (VNTR) analysis (MLVA) is now widely used for the genotyping of many different pathogenic bacteria (18, 30, 42). Each strain is described by a code corresponding to the number of repeats at the selected VNTR. These codes can be easily compared between laboratories through web-based databases (WebServices), such as the one available at http://bacterial-genotyping.igmors.u-psud.fr (21). We previously described a small collection of VNTR markers for the typing of P. aeruginosa and showed that the clustering achieved by MLVA was similar to that achieved by ribotyping and PFGE (27). We have now added new markers to the genotyping scheme and improved the PCR amplification, which make the assay more robust and significantly increase the amount of information provided. With the present longitudinal study of P. aeruginosa isolates from children with CF, we demonstrate that MLVA constitutes a very robust method for the epidemiological surveillance of P. aeruginosa infections.
|
|
|---|
Microbiology. Sputum samples were inoculated onto sheep blood agar and cysteine, lactose, electrolyte-deficient agar (Oxoid, Dardilly, France). After 2 days of incubation at 35°C, colonies that looked nonidentical were picked and tested for an oxidase reaction. The biochemical identification of P. aeruginosa species was performed by standard techniques, and antimicrobial susceptibility was performed by disk diffusion. By using the routine O-polysaccharide typing system, mucoid strains (PMU) were usually nonserotypable (polyagglutinable), especially for the patients chronically colonized with P. aeruginosa. Among the nonmucoid strains, many strains were nontypeable (PNT). Different isolates from a single patient sample were recovered when they showed different serotypes or phenotypes (mucoid or nonmucoid) or when more than one difference in the antimicrobial susceptibility pattern (22 antibiotics) was observed. Isolates were preserved at –80°C in brain heart broth (bioMerieux, Marcy l'Etoile, France) with 10% glycerol (Sigma-Aldrich, Saint-Quentin Fallavier, France).
A total of 24 isolates from ICU patients and 163 isolates from CF patients were analyzed. In addition, 50 isolates from non-CF patients that had previously been genotyped by MLVA with six VNTRs and that were representative of the major groups described by Onteniente et al. (27) were analyzed with the new VNTRs.
Strains C50 (a clinical isolate) and SG17M (an environmental isolate) belonging to the widely distributed "clone C" were a generous gift from Ute Römling (Stockholm, Sweden) (34).
Reference strain PAO1 was purchased from the Institut Pasteur culture collection. Alcaligenes xylosoxidans, Burkholderia cepacia, and Stenotrophomonas maltophilia (one, two, and six isolates, respectively) were isolated from the sputum of CF patients. Twelve DNA samples from seven different Pseudomonas species (two P. poae isolates, one P. tolaasii isolate, one P. trivialis isolate, three P. graminis isolates, two P. orientalis isolates, two P. fluorescens isolates, and one P. putida isolates) were provided by the Centre d'Etudes du Bouchet's collection of environmental strains and related genomic DNA resources (Vincent Ramisse, Vert le Petit, France).
DNA purification. DNA was purified with a DNeasy tissue kit (QIAGEN, Courtaboeuf, France) or, alternatively, by the classical cetyltrimethylammonium bromide (CTAB)-phenol extraction method. Bacteria were lysed into a solution containing 10 mM Tris HCl, pH 8, 10 mM EDTA, 10 mM NaCl, and 0.5% sodium dodecyl sulfate and were incubated overnight at 37°C with 100 µg/ml proteinase K. One hundred microliters of 5 M NaCl was added to 0.6 ml lysate (final concentration, 0.7 M), followed, after homogenization, by the addition of 40 µl of 10% CTAB in 0.7 M NaCl (final CTAB concentration, 0.5%). After 10 min at 65°C, the CTAB precipitate was extracted with 1 volume of chloroform, and the supernatant was transferred into a fresh tube. The DNA was purified by three successive extractions with phenol (pH 7.5), phenol-chloroform (1/1), and chloroform. The nucleic acids were precipitated with 2 M NaCl and 2 volumes of ethanol. After centrifugation the pellet was suspended in TE buffer (10 mM Tris HCl, pH 7.5, 1 mM EDTA). The quality and the concentration of DNA were measured with an ND-1000 spectrophotometer (NanoDrop; Labtech, Palaiseau, France).
Genotyping. In addition to the markers described by Onteniente et al. (27), 11 new polymorphic tandem repeats were identified in the sequenced genomes of reference strains PAO1 and PA14 by using the strain comparison tool developed by Denoeud and Vergnaud (8), available at http://minisatellites.u-psud.fr/ (Table 1). Oligonucleotide primers targeting the 5' and 3' flanking regions of the VNTR loci were used for amplification. PCRs were performed in reaction mixtures of 15 µl containing 5 to 10 ng of DNA, 1x PCR buffer, 1.5 mM MgCl2, 1 U of Taq DNA polymerase (QIAGEN), 200 µM each deoxynucleoside triphosphate, and 0.3 µM each flanking primer (Eurogentec, Angers, France) in the presence of 0.5 M betain, as described previously (14). Amplification was performed with a PTC 200 thermocycler (Bio-Rad, Marnes-la-Coquette, France) under the following conditions: an initial denaturation cycle for 5 min at 94°C and 35 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 60°C, and elongation for 45 s at 72°C, plus a final elongation step for 10 min at 72°C. For the analysis of all markers except ms207 and ms209, 2 µl of each of the PCR products was separated in a 2% agarose gel (routine-use grade; Eurogentec, Angers, France). Electrophoresis was performed in 20-cm-wide gels made in 0.5x TBE (Tris-borate-EDTA) buffer (Sigma) and run at 8 V/cm. Reference strain PAO1 was included in each PCR run. The 100-bp ladder DNA size marker was from MBI Fermentas (Euromedex, Souffelweyersheim, France). After the run the gels were stained in 0.5 to 1.0 µg/ml ethidium bromide for 15 to 30 min and then rinsed with water and photographed under UV illumination (Vilber-Lourmat, Marne la Vallée, France).
|
View this table: [in a new window] |
TABLE 1. VNTR characteristics
|
To help with the conversion of the allele size in base pairs into the number of repeats, we propose on a dedicated website (http://bacterial-genotyping.igmors.u-psud.fr/pseudomonas/) a chart showing the different alleles observed in our collection of more than 200 isolates. This chart will be updated when new alleles are encountered.
Nomenclature and description of MLVA profiles. The repeat length and the number of repeat units in the different sequenced genomes were determined by using the Microbial Tandem Repeats Database (http://minisatellites.u-psud.fr) (8, 22). The amplification of DNA from reference strain PAO1 with the primers described in Table 1 produced amplicons of the expected sizes. The number of repeats in new alleles was estimated by subtracting the invariable flanking region from the amplicon size and then dividing by the repeat unit length determined for reference strain PAO1. Intermediately sized alleles (which may result from intermediately sized repeat units or from small deletions in the flanking sequence) were reported as half sizes, when they were observed. Alleles of unexpected size were sequenced, and the sequences have been deposited in the EMBL sequence database. The "NA" (not amplified) designation was given when no amplification was repeatedly observed at a given locus.
The polymorphism index of individual or combined VNTR loci was calculated by use of the Hunter-Gaston discriminatory index (HGDI) (15), an application of Simpson' s index of diversity (36). This index evaluates the probability that two unrelated strains will be characterized as the same type. It is determined by the number of types defined by the test method and the relative frequencies of these types. The authors suggest that an index of greater than 0.90 is desirable if typing results are to be interpreted with confidence.
The MLVA genotype of an isolate with 15 VNTRs (MLVA15) is expressed as its allelic profile corresponding to the number of repeats at each VNTR in the order ms77, ms127, ms142, ms172, ms211, ms212, ms213, ms214, ms215, ms216, ms217, ms222, ms223, ms207, and ms209. The genotype of PAO1 deduced from its genomic sequence is 4 8 7 12 5 9 5 3 4 3 2 2 4 7 6. The genotype of strain PA14 deduced from its genomic sequence is 2 9 1 12 2 4 1 5 2 1 5 2 4 5 6. A new genotype number is given when one difference is observed at any VNTR. Lineages are defined as groups of isolates for which the genotype differs at a maximum of two VNTRs. In the clustering analysis by use of the categorical coefficient (also called Hamming's distance), this corresponds to an interval of 85 to 100% similarity. Lineages have been arbitrarily numbered in the order in which they are listed in the clustering analysis.
Nucleotide sequence accession numbers. The sequences of the alleles of unexpected sizes have been deposited in the EMBL sequence database under accession numbers AM773730 to AM773750.
|
|
|---|
As a first test of efficiency for the MLVA15 scheme (MLVA with 13 minisatellites and 2 microsatellites), we genotyped isolates from patients in the ICU panel (Table 2). Only nonmucoid bacteria were isolated from this panel; they were agglutinable in most of the cases and could therefore be serotyped. Amplification with the 15 markers was observed with all the isolates except for ms223 from patient ICU-06 and ms212 from patient ICU-08 (Table 2). When several isolates were recovered from a single patient, they showed the same MLVA profile, as illustrated for the six isolates recovered over a 6-month period from patient ICU-06, the three isolates from patient ICU-13, and the two isolates from patients ICU-07 and ICU-14. Isolates Tr20, Tr18, and Tr14, from patients ICU-02, ICU-03, and ICU-04, respectively, had the same serotype (P6) and an identical genotype except for ms214, suggesting that these patients were infected by variants of the same strain. They were present in the hospital within a period of 2 months. The other patients had unique strains with large genotype differences. In isolate Tr19 from patient ICU-10, the ms216 amplification product was about 1.5 kb, which is unusually large. Sequencing showed the presence of an insertion sequence (IS) in the tandem repeat (see the dedicated paragraph below). Each lineage was named according to the criteria defined in the Materials and Methods section.
|
View this table: [in a new window] |
TABLE 2. Genotypes of reference strains PAO1 and PA14 and additional characteristics of 24 isolates from 15 patients in the ICU
|
Longitudinal analysis of P. aeruginosa infection in CF patients. We then analyzed systematically all the P. aeruginosa isolates recovered from the CF patients over a period of 3 years (Table 3). They were typed by MLVA15 and, together with the ICU isolates and reference strains PAO1 and PA14, were grouped according to genotype after a clustering analysis was performed with BioNumerics software by use of Hamming's distance (the categorical coefficient) and the unweighted pair group method with arithmetic means clustering method (see Figure S2 in the supplemental material). Among the 163 P. aeruginosa isolates from 46 CF patients, 39 lineages were observed (Table 3). Seven lineages were shared by two different patients (lineages 11, 23, and 51), three different patients (lineages 1 and 21), and up to four different patients (lineages 3 and 25); but a single lineage was commonly found in a patient, either with a nonmucoid (O-agglutinable or nonagglutinable) or a mucoid phenotype. Six patients harbored two different strains: CFU-05 (lineages 21 and 48), CFU-06 (lineages 26 and 24), CFU-07 (lineages 25 and 44), CFU-09 (lineages 1 and 46), CFU-13 (lineages 23 and 16), and CFU-33 (lineages 21 and 33). In four cases, one of these lineages was shared with other patients (lineages 1, 21, 23, and 25). For patients CFU-19, CFU-27, and CFU-33, a serotypeable strain corresponding to lineages 23, 1, and 21, respectively, was isolated at primary colonization, while nonserotypable (mucoid or nonmucoid) isolates from these lineages chronically infected several other patients. Interestingly, one strain from patient CFU-06 belonged to the same lineage (lineage 51) as two isolates belonging to clone C described by Römling et al. (34), isolates SG17M and C50, as shown in Fig. 1 (lanes 2, 5, and 6). The strain from patient CFU-06 differed from the other two strains only at ms207, one of the microsatellites. Similarly, one isolate from patients CFU-16 and CFU-38 had the same genotype as that of reference strain PA14, as deduced from the sequenced genome (20) (TR_S0500826, alias Tr60, from patient CFU-16 is shown in Fig. 1, lane 4).
|
View this table: [in a new window] |
TABLE 3. Characteristics of isolates from CF patients
|
![]() View larger version (116K): [in a new window] |
FIG. 1. Agarose gel electrophoresis of amplicons from 13 VNTRs in six P. aeruginosa isolates. Each group of six samples corresponds to strains PAO1, SG17, Tr42, Tr60, C50, and Tr40, respectively, and is separated by a 100-bp ladder. The amplicons in strains SG17, C50, and Tr40 are circled. The numbers on the left are in base pairs.
|
|
|
|---|
In this study we analyzed isolates from CF patients, as well as non-CF patients with different diseases caused by nosocomially acquired P. aeruginosa infections, in the Armand Trousseau Hospital (ICU patients) as well as in different European hospitals (27). The P. aeruginosa isolates from the CF and the non-CF patients were not distributed differently in the clustering analysis, although clones which chronically infected several CF patients were not found elsewhere.
The specificity of the assay was demonstrated by testing isolates from seven other Pseudomonas species as well as bacteria from other genera frequently found in the airways of CF patients (19). This showed that amplification of the 15 VNTRs could be obtained only with P. aeruginosa isolates. Furthermore, on two occasions during this study, isolates that could not be genotyped by MLVA15 turned out to be Pantoea spp. that had been misidentified as P. aeruginosa.
Stability of the VNTRs. The MLVA genotype of the strains recovered from an individual patient over time is remarkably stable, except for the occasional insertion of an IS element and the addition or deletion of repeats in a single VNTR, generally a microsatellite. For example, among seven isolates from patient CFU-05 that were analyzed (from 9 June 2004 to 4 January 2006), the last one differed from the others at microsatellites ms207 and ms209 by the loss of one repeat. Ten isolates from patient CFU-13 were analyzed from 2 February 2005 to 9 January 2006, and the isolates showed the same genotype, except for the presence of an IS in marker ms212 in one of the isolates.
Most of the VNTRs belong to a family of intergenic elements that can form hairpin secondary structures reminiscent of those of regulatory sequences such as the bacterial interspersed mosaic elements described in Escherichia coli (2). The presence of an IS and, in particular, the presence of ISPa11 was observed at least once in all these markers. A search of the PAO1 sequence showed the presence of this IS in additional elements not included in our MLVA scheme (40). It has previously been shown that intergenic repeated sequences were the target for the insertion of IS in Pseudomonas putida (33) as well as several other bacteria (40).
Longitudinal study of P. aeruginosa colonization. Treatment of most of the patients with primary colonization with combinations of antimicrobial agents seemed to be efficient, since P. aeruginosa was not isolated by our routine culture procedure several months after treatment (see Table S1 in the supplemental material). In 7 patients, the genotype of the strain causing the primary colonization was similar to the genotype associated with chronic colonization in other patients. Three patients (patients CFU-19, CFU-27, and CFU-33) were newly colonized with a serotypeable (agglutinable) strain that showed the same genotype as nonagglutinable (mucoid or nonmucoid) strains from chronically infected patients. This may be explained by a reversion of the nonagglutinable phenotype or by the existence of a reservoir of nonmucoid bacteria. A similar observation was made by Jelsbak et al., who further demonstrated that nonmucoid isolates in newly colonized patients were mucoid revertants (16).
Most of the CF patients were already colonized at the start of the present study, and they usually harbored a single strain, which persisted over an 18- to 24-month period, despite antibiotic treatment. Both mucoid and nonmucoid variants with the same genotype were isolated, as has been observed previously in CF patients (4, 24).
Are some lineages particularly prone to colonization of CF patients? Almost half of the CF patients were infected with strains whose VNTR patterns were highly similar to those of strains found in other CF patients. Strains with VNTR patterns identical to that of the PA14 reference strain (at the 15 markers tested) were isolated from two newly colonized patients (patients CFU-16 and CFU-38, lineage 51) and from another non-CF patient with primary ciliary dyskinesia attending the Trousseau CF Center (data not shown). In the three cases, the isolates were sensitive to several antibiotics, and infection was cleared following treatment. Strain PA14 was originally isolated from a burn patient and has been shown to be highly virulent for plants and animals (32). We further confirmed the identity between these isolates and PA14 by sequencing a particular tandem repeat structure, the CRISPR locus (31), which is present in some strains of P. aeruginosa and which is characterized by an important degree of variability (data not shown). The CRISPR sequence in the three isolates was exactly the same as that in PA14, whereas a high degree of diversity was observed in nonrelated isolates (data not shown). Another argument for the high degree of similarity between these isolates and PA14 is the presence of the pathogenicity island PAPI-1 (13), as assessed by PCR amplification of the RL038 and RL078 genes (data not shown). The basis for the pathogenicity of this strain is not known. Recent investigations suggested that its virulence may be multifactorial and combinatorial (20). The VNTR pattern of lineage 26 corresponds to that of clone C, another lineage that is distributed worldwide and that is frequently observed in CF patients. These clones of pathogenic P. aeruginosa may infect patients other than those in CF clinics, suggesting that they are probably widely distributed in the environment. Finally, six additional lineages described in the present study have been identified in CF patients in Sweden (Ewa Johansson, personal communication).
Widespread clones of P. aeruginosa have previously been isolated from patients attending pediatric CF centers (1). The spread of particular clones was sometimes related to antibiotic resistance (6, 17). A large study in England and Wales suggested that some clones were distributed among different CF centers (35). A recent study in Denmark investigating P. aeruginosa populations in CF patients also reported the existence of dominant clones that proved to be highly successful colonizers of the airways of CF patients (16).
Studies on the population structure of P. aeruginosa revealed the existence of clonal complexes in clinical and environmental isolates (29, 43). In the study by Wiehlmann et al. of 240 P. aeruginosa strains from diverse habitats and of diverse geographic origins, the majority of strains belonged to few dominant clones, and the most frequent genotype was represented by strain PA14 (43).
Since most of our patients seemed to have no contact with each other outside the CF center (the exceptions were two brothers, patients ICE-27 and ICU-45, who did not share the same strain), an epidemiological study will be performed to clarify the origins of apparent cross transmission of some P. aeruginosa lineages and the possibility of a common source of infection within the center or from an unidentified environmental source. It is not known whether these clones are more virulent than sporadic clones, and studies by use of, for example, the Caenorhabditis elegans killing assay will need to be performed (38).
Conclusion. This study demonstrates that MLVA is a very robust genotyping technique which can be applied to the systematic survey of P. aeruginosa isolates in a CF clinic. Future developments of the MLVA procedure can be achieved by using a sequencer in combination with different fluorochromes and loci with different PCR size ranges. An isolate could then be genotyped in a single run either by mixing the products after the PCR or by performing a multiplex PCR.
The characterization of germs that chronically infect CF patients is of major importance for improving the treatment of these patients. To this purpose, VNTR-based genotyping assays will be applied to the systematic analysis of other germs and in particular to Staphylococcus aureus and Burkholderia spp., for which specific MLVA schemes have been developed.
MLVA allows the comparison of isolates between different centers through exchanges of VNTR profiles. These profiles and associated lineages will be stored in databases. As such, we propose a genotyping page on a public genotyping website in which MLVA profiles can be compared to those of the present strain collection (http://bacterial-genotyping.igmors.u-psud.fr/). We believe that such tools will help address the problem of the worldwide distribution of pathogenic clones and investigation of the basis for their pathogenicity.
This study was performed with the support of the association Vaincre La Mucoviscidose (grant RC0630). The development of tools for the surveillance of bacterial pathogens is supported by the French Délégation Générale pour l'Armement.
Published ahead of print on 15 August 2007. ![]()
Supplemental material for this article may be found at http://jcm.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»